



Supplementary Fig. 1. Efficacy of tofacitinib and upadacitinib both in JAK inhibitor-exposed cases and in JAK inhibitor-naïve cases. (A) Response rates at 24 weeks of tofacitinib (n=3) and upadacitinib (n=18) in JAK inhibitor-exposed patients. (B) Response rates at 24 weeks of tofacitinib (n=65) and upadacitinib (n=16) in JAK inhibitor-naïve patients. Statistical significance was analyzed using a Fisher exact test; ^aP<0.05. JAK, Janus kinase; NS, not significant.